Table 3.
Comparison of DMT initiation and switching from pre- to post-pandemic
| Initiation—OR (95% CI) | Switching—OR (95% CI) | |
|---|---|---|
| Anti-CD20 mAb | ||
| Ocrelizumab, ofatumumab and rituximab | 1.26 (1.06–1.49) | 1.15 (1.02–1.29) |
| Oral immunomodulators | ||
| Dimethyl fumarate | 1.76 (1.49–2.09) | 0.85 (0.69–1.05) |
| Teriflunomide | 0.77 (0.62–0.96) | 0.80 (0.64–0.99) |
| Fingolimod | 0.55 (0.41–0.73) | 0.49 (0.41–0.58) |
| Injectable immunomodulators | ||
| BRACE | 0.78 (0.62–0.99) | 0.78 (0.62–0.99) |
| Integrin antagonist | ||
| Natalizumab | 1.72 (1.39–2.13) | 1.66 (1.40–1.98) |
| Purine analogue | ||
| Cladribine | 1.43 (1.09–1.87) | 1.67 (1.41–1.98) |
| Other | ||
| Alemtuzumab | 0.27 (0.15–0.48) | 0.27 (0.17–0.44) |
BRACE includes interferon-beta and glatiramer acetate, and anti-CD20 mAbs includes rituximab, ocrelizumab and ofatumumab. Data are displayed with Odds ratios and 95% CI